Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Special Drug Use Investigation of EYLEA for AMD

Authors not listed

Bayer · 2012

Abstract

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD). The objective of this study is to assess safety and effectiveness of EYLEA using in real clinical practice. A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational period. An annual follow-up survey will be conducted for 5 years at the longest after standard observational period.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Anonymous. (2012). Special Drug Use Investigation of EYLEA for AMD. <em>Bayer</em>. https://clinicaltrials.gov/study/NCT01756248
Vancouver
Anonymous. Special Drug Use Investigation of EYLEA for AMD. Bayer. 2012.
BibTeX
@misc{anon2012Specia, title = {Special Drug Use Investigation of EYLEA for AMD}, author = {Anonymous}, journal = {Bayer}, year = {2012}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings